Off-targeting oft-targeted CD20 in cHL
- PMID: 22555658
- DOI: 10.1182/blood-2012-03-413146
Off-targeting oft-targeted CD20 in cHL
Abstract
We now think of classical Hodgkin lymphoma (cHL) as derived from "crippled" germinal center B cells that have frequently acquired rearranged and somatically mutated Ig genes.1,2 Despite their B-cell origin, the malignant Hodgkin and Reed-Sternberg (HRS) cells have lost most of the superficial trappings of B cells and therefore have been hidden from investigators' lenses for decades, prompting an arduous but persistent race to uncover the mystery of the HRS cell.
Comment on
-
Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma.Blood. 2012 May 3;119(18):4129-32. doi: 10.1182/blood-2012-01-402792. Epub 2012 Feb 16. Blood. 2012. PMID: 22343727 Free PMC article. Clinical Trial.
-
Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma.Blood. 2012 May 3;119(18):4123-8. doi: 10.1182/blood-2012-01-405456. Epub 2012 Feb 27. Blood. 2012. PMID: 22371887 Free PMC article. Clinical Trial.
Publication types
LinkOut - more resources
Full Text Sources